Intersect ENT (NASDAQ:XENT) insider Lisa D. Earnhardt sold 15,000 shares of the business’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $38.32, for a total value of $574,800.00. Following the completion of the transaction, the insider now owns 499,683 shares in the company, valued at approximately $19,147,852.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of XENT opened at $36.60 on Friday. Intersect ENT has a one year low of $15.90 and a one year high of $40.00.
Intersect ENT (NASDAQ:XENT) last issued its earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.06. Intersect ENT had a negative net margin of 16.99% and a negative return on equity of 14.40%. The business had revenue of $29.53 million for the quarter, compared to analyst estimates of $29.45 million. analysts expect that Intersect ENT will post -0.61 EPS for the current year.
Several equities research analysts have recently commented on XENT shares. Guggenheim reissued a “buy” rating on shares of Intersect ENT in a research note on Thursday, March 1st. Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price target on shares of Intersect ENT in a report on Monday, December 11th. JPMorgan Chase upgraded Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. BidaskClub downgraded Intersect ENT from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. Finally, Zacks Investment Research raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $33.38.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC increased its stake in Intersect ENT by 22.4% in the fourth quarter. Jennison Associates LLC now owns 2,036,202 shares of the medical equipment provider’s stock valued at $65,973,000 after purchasing an additional 372,320 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Intersect ENT by 2.0% in the fourth quarter. BlackRock Inc. now owns 1,980,942 shares of the medical equipment provider’s stock valued at $64,183,000 after buying an additional 39,761 shares during the period. Alliancebernstein L.P. boosted its holdings in Intersect ENT by 12.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,466,730 shares of the medical equipment provider’s stock worth $47,522,000 after purchasing an additional 161,723 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in Intersect ENT by 8.0% during the third quarter. Neuberger Berman Group LLC now owns 802,521 shares of the medical equipment provider’s stock worth $24,999,000 after purchasing an additional 59,620 shares during the last quarter. Finally, State Street Corp boosted its holdings in Intersect ENT by 33.6% during the second quarter. State Street Corp now owns 552,344 shares of the medical equipment provider’s stock worth $15,437,000 after purchasing an additional 138,968 shares during the last quarter. 84.49% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Intersect ENT (NASDAQ:XENT) Insider Sells $574,800.00 in Stock” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/intersect-ent-inc-xent-insider-lisa-d-earnhardt-sells-15000-shares.html.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.